Veradigm Inc.

OTCPK:MDRX Stock Report

Market Cap: US$1.5b

Veradigm Future Growth

Future criteria checks 0/6

Veradigm's revenue is forecast to decline at 23.5% per annum. EPS is expected to grow by 0.9% per annum.

Key information

n/a

Earnings growth rate

0.9%

EPS growth rate

Healthcare Services earnings growth32.7%
Revenue growth rate-23.5%
Future return on equityn/a
Analyst coverage

Low

Last updated31 Dec 2024

Recent future growth updates

Recent updates

Veradigm (NASDAQ:MDRX) Is Doing The Right Things To Multiply Its Share Price

Feb 28
Veradigm (NASDAQ:MDRX) Is Doing The Right Things To Multiply Its Share Price

Veradigm (NASDAQ:MDRX) Might Have The Makings Of A Multi-Bagger

Nov 10
Veradigm (NASDAQ:MDRX) Might Have The Makings Of A Multi-Bagger

Veradigm's (NASDAQ:MDRX) Returns On Capital Are Heading Higher

Mar 06
Veradigm's (NASDAQ:MDRX) Returns On Capital Are Heading Higher

Is It Too Late To Consider Buying Veradigm Inc. (NASDAQ:MDRX)?

Feb 13
Is It Too Late To Consider Buying Veradigm Inc. (NASDAQ:MDRX)?

Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 22
Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate

These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well

Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)

Dec 03
Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)

Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%

Sep 28

Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?

Sep 17
Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?

Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist

Aug 24
Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist

We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt

Jul 31
We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt

Is Now An Opportune Moment To Examine Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)?

Jun 15
Is Now An Opportune Moment To Examine Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)?

Earnings and Revenue Growth Forecasts

OTCPK:MDRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025677N/AN/AN/A2
12/31/2024650N/AN/AN/A3
12/31/2023631N/AN/AN/A2
12/31/2022617-4N/AN/A2
9/30/20221,52911682161N/A
6/30/20221,522125107189N/A
3/31/20221,512148-91-11N/A
12/31/20211,503134-154-75N/A
9/30/2021806-14-373-319N/A
6/30/20211,027-48-388-322N/A
3/31/20211,255-96-183-98N/A
12/31/20201,503-133-212-107N/A
9/30/20201,428-143-1584N/A
6/30/20201,507-134-4467N/A
3/31/20201,582-263-7937N/A
12/31/20191,633-238-7446N/A
9/30/20191,763-197-11920N/A
6/30/20191,751-203-138-1N/A
3/31/20191,74834-12915N/A
12/31/20181,618-39-6668N/A
9/30/20181,5167073188N/A
6/30/20181,53354105237N/A
3/31/20181,518-187120262N/A
12/31/20171,498-183122279N/A
9/30/20171,714-21067257N/A
6/30/20171,657-19165246N/A
3/31/20171,618-48105269N/A
12/31/20161,38631145269N/A
9/30/20161,470-2153268N/A
6/30/20161,4323N/A255N/A
3/31/20161,39710N/A229N/A
12/31/20151,386-2N/A212N/A
9/30/20151,382-21N/A180N/A
6/30/20151,373-41N/A154N/A
3/31/20151,372-56N/A141N/A
12/31/20141,378-66N/A103N/A
9/30/20141,388-85N/A70N/A
6/30/20141,373-108N/A68N/A
3/31/20141,366-113N/A63N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MDRX's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if MDRX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if MDRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MDRX's revenue is expected to decline over the next 3 years (-23.5% per year).

High Growth Revenue: MDRX's revenue is forecast to decline over the next 3 years (-23.5% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MDRX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/19 20:34
End of Day Share Price 2025/01/17 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Veradigm Inc. is covered by 45 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Gregory BolanAvondale Partners
Matthew GillmorBaird